Dermal Fillers for Ozempic Face: What the Evidence Shows (and Doesn't)

Start with our pillar guide: How to Fix Ozempic Face: What the Evidence Supports (2026), or browse all GLP-1 & Skin articles.

Dermal fillers for Ozempic face can restore some lost cheek and jawline volume, but the evidence is thin. The only sizable study was an open-label trial of 41 people, funded and designed by filler maker Galderma, and it had no control group. Everything else is case series and expert opinion. Fillers add volume. They do not tighten loose skin. Evidence: limited.

"Ozempic face" is an informal name for the hollowed, older-looking face some people notice after losing weight on a GLP-1 medication such as semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound). It is not a diagnosis. For the full picture of causes and non-injectable options, see our guide to what actually helps Ozempic face. This article covers only injectables: what was studied, who paid for the studies, and what nobody has tested yet.

Key takeaways

• Facial fat shrinks roughly in step with weight lost. One imaging study of 20 GLP-1 users found about 7% midface volume loss per 10 kg of weight lost (Sharma et al., 2025).
• The largest GLP-1 filler study (Sculptra plus Restylane, n=41) was funded, designed and analyzed by Galderma, the maker of both products. It was open-label with no control group (Lorenc et al., 2026).
• Whether to wait for stable weight or start early is expert opinion. No trial compares the two approaches.
• Case reports describe nodules in old filler after people started compounded tirzepatide. A published letter argues infection wasn't ruled out.
• No topical product, peptides included, has been tested in GLP-1 users.

Never stop, skip or change a GLP-1 medication for skincare reasons; talk to your prescriber first. Nothing in this article is a reason to adjust your dose.

What causes the volume loss that dermal fillers for Ozempic face try to replace?

The main cause is fat loss in the face, especially in the superficial fat pads that sit just under the skin. Current evidence ties this to the weight loss itself. No study shows a direct drug effect on facial tissue.

The only objective measurement in GLP-1 users comes from a Vanderbilt study. Sharma and colleagues reviewed CT or MRI scans taken before and after a GLP-1 prescription in 20 patients (median age 54, mean follow-up 321 days, mean weight loss 11.0 kg). Median midface volume fell 9.0%: 11% in superficial fat and 7% in deep fat. That works out to about 7% of midface volume per 10 kg lost (Sharma et al., 2025; retrospective cohort, funding not reported). Evidence: early / preliminary.

Older weight-loss research points the same way, with some nuance:

• A systematic review of 13 studies plus 1 abstract on surgical and medical weight loss found the most volume loss in the mid-cheek, along with laxity of the central neck skin (Jafar et al., 2024; funding not reported). Evidence: limited.
• Forty blinded raters judged 7 people who had lost more than 100 lb as looking 5.1 years older than their actual age before a facelift. The study had 11 controls (Couto et al., 2015; retrospective, Cleveland Clinic). Evidence: early / preliminary.
• In a photo study of 14 bariatric patients, about 100 survey raters judged them older but more attractive after weight loss. Only 5 of the 14 showed a significant change in perceived age (Papoian et al., 2015; no conflicts declared). Evidence: early / preliminary.

Interest in fillers has followed the headlines. A 2025 systematic review by Daneshgaran and colleagues covered 23 plastic-surgery articles and found that searches for "Ozempic face" were linked to searches for "face filler" and "plastic surgeons." The authors described GLP-1 drugs as causing "morphological changes resembling advanced aging" but said the literature was "limited by study biases" (Daneshgaran et al., 2025; no funding or conflicts declared). A separate Google Trends analysis covering June 2022 to June 2025 found that "Ozempic face" interest tracked filler searches, not surgery searches (Mnajjed et al., 2025).

What does the research show about dermal fillers for Ozempic face?

There is one manufacturer-run study of 41 people, a 4-person case series and a few reports without published numbers. Nobody has run a randomized, controlled trial of any filler in GLP-1 users.

Sculptra plus Restylane: the Galderma study

Lorenc and colleagues ran a multicenter, open-label study in 41 people with facial changes after GLP-1 weight loss. Participants had 2 to 3 sessions of Sculptra (poly-L-lactic acid, or PLLA) plus 1 to 2 sessions of Restylane Lyft or Restylane Contour (hyaluronic acid fillers), with follow-up to 9 months. The authors reported improved skin quality (hydration, radiance) and better cheek, jawline and perioral contour, with no treatment-related adverse events (Lorenc et al., 2026; NCT06351358).

Context matters for this study:

• Funding and design: The full text states the study was funded by Galderma Laboratories, LP, which makes both Sculptra and Restylane. Galderma designed the study and analyzed the data.
• Authors: 4 co-authors were Galderma employees, one of them former.
• No comparison group: Every participant got treatment, so the study can't show how much change came from the injections and how much came from time, weight shifts or expectation.
• The 91.4% figure: The widely quoted claim that 91.4% of participants "would recommend the injection regimen" comes from a subject-reported satisfaction survey in the full text. It measures how satisfied people were, not how well the treatment worked.

Evidence: limited (single manufacturer-funded, uncontrolled study).

Radiesse: a 4-person case series

Durairaj and colleagues retrospectively reviewed 4 patients treated with hyperdilute Radiesse in the lower face. Radiesse is calcium hydroxylapatite (CaHA) in a carboxymethylcellulose (CMC) gel. Over 6 months, the patients lost 9.2% of body weight, yet their facial measurements stayed stable or improved, and all were rated "improved" or "much improved" (Durairaj et al., 2025).

The authors report no financial support for this article. However, Durairaj received a product grant from Merz (the maker of Radiesse) for the primary study and has honoraria from Galderma, Merz and Allergan, and a co-author is employed by Merz. Evidence: early / preliminary.

Other reports

Brazilian plastic surgeons published a report on PLLA combined with HA filler after semaglutide weight loss. PubMed lists no abstract and no funding statement, so we can't report its results (Sarlos et al., 2025).

Which filler types are used for Ozempic face, and how do they differ?

Clinicians mainly use hyaluronic acid fillers, which add volume right away, and biostimulators, which are meant to prompt gradual tissue response. The table summarizes what's been studied in GLP-1 users specifically.

How long do results last? We can't give a sourced figure for HA fillers in GLP-1 users. A 2026 narrative review of PLLA says its effects "persist for 2 years or longer," but several of its authors are affiliated with Galderma, which makes Sculptra (Franco et al., 2026). Evidence: expert opinion. Durability may also differ when weight is still changing, and no study has tracked that.

When should you get dermal fillers for Ozempic face: wait or start early?

Nobody knows the best timing. Experts disagree, and no trial has compared waiting with starting early.

The case for waiting. A recurring theme in GLP-1 communities is to wait until weight is stable, because filler placed mid-loss may look different as the face keeps changing. Weight can also shift after treatment stops. In the STEP 1 trial, semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks (Wilding et al., 2021; RCT). In the off-treatment extension, participants had regained about two-thirds of that loss (11.6 percentage points) by week 120 (Wilding et al., 2022). Neither study measured faces.

The case for starting early. A 2026 narrative review argues for early biostimulation plus targeted HA, on the reasoning that GLP-1 face involves superficial fat deflation, loss of deep support, bone resorption and laxity (Frank et al., 2026; academic and private-practice authors, funding not reported). The 4-person Radiesse series also treated patients while they were still losing weight.

Where consensus stands. A 4-clinician consensus paper says timing within the weight-loss journey should be considered and favors combining HA with biostimulators. The same paper admits these treatments "have not yet been widely studied in this population" (Moradi et al., 2026). Allergan Aesthetics (AbbVie) funded the writing support, one author is an Allergan employee, and Moradi consults for AbbVie, Galderma, Merz, Evolus and Teoxane. Evidence: expert opinion.

Your injector's timing advice is a judgment call, not a proven rule. Changing your medication to protect your face hasn't been studied at all, so any dose question belongs with your prescriber.

Are dermal fillers safe while on a GLP-1 medication?

No controlled study has looked at filler safety in GLP-1 users. The Galderma study reported no treatment-related adverse events in 41 people, and a few case reports raise questions that remain unresolved.

Nodule case reports. Two 2026 case reports in JAAD Case Reports describe facial nodules appearing in filler placed earlier, after the patients started compounded tirzepatide (Luke et al., 2026; Moore et al., 2026). A published letter in response argues that infection or biofilm (a bacterial film that can form on implanted material) wasn't excluded (letter, 2026). Case reports can't show cause, and compounded products aren't the same as FDA-approved brands. If you have filler and plan to start a GLP-1, or the reverse, tell both your prescriber and your injector. Evidence: case reports only.

Skin sensitivity. The current Wegovy label lists dysesthesia among its most common adverse reactions. Dysesthesia means abnormal skin sensations such as burning, tingling or pain from light touch. In the label, it occurred in 2% of adults on 2.4 mg vs 1% on placebo, and in the 7.2 mg trial in 22% on 7.2 mg vs 6% on 2.4 mg vs 0% on placebo (Wegovy prescribing information, DailyMed, revised 06/2026). No study connects this to filler outcomes. Still, mention it at a consultation. We cover it in detail in GLP-1 skin sensitivity and burning.

What FDA reports show. We searched openFDA's adverse event database (FAERS) on Oct 10, 2026, at 2:29 PM CT, by generic name (semaglutide, tirzepatide) and exact MedDRA reaction terms. Each count covers reports listing the drug in any role, suspect or concomitant (example query).

FAERS reports show what patients and clinicians reported while on a drug. They don't show that the drug caused the event, and they can't be used to estimate how often it happens. Reports are voluntary and unverified, may be duplicated, rise with media attention and have no denominator. The counts also partly reflect how many people use each drug, so they can't be used to compare semaglutide with tirzepatide. Mainly, the table shows that people rarely report facial volume loss as a drug reaction, which makes FAERS useless for estimating how common Ozempic face is.

What can't dermal fillers for Ozempic face fix?

Fillers replace volume. They don't remove or tighten loose skin, and they don't stop further changes if weight keeps shifting.

A 2023 review of Ozempic face lays out fillers, skin-tightening procedures and surgery as separate options for different problems. It also notes that prescribers "seldom counsel" patients about facial changes (Humphrey et al., 2023; narrative review, no conflicts declared). Evidence: expert opinion.

Two patterns come up often in GLP-1 and over-45 skincare communities. Some people say biostimulators helped their volume and texture but not jowls or true sagging. Others say injectors sent them toward energy devices or surgery for neck laxity instead of filler. These are anecdotes, not evidence, but they match the reviews above. Neck laxity is its own topic, covered in Ozempic neck.

Another frequent question is whether semaglutide itself damages collagen. No human study shows a direct drug effect on skin collagen. The nearest data come from weight loss in general. A controlled histology study compared abdominal skin from 40 post-bariatric women with 40 never-obese women and found less collagen in the post-bariatric group, but elastic fibers were not damaged (Orpheu et al., 2010; academic, São Paulo). That is abdominal skin after surgery, not facial skin on a GLP-1. Evidence: limited.

Can skincare or peptides help alongside dermal fillers for Ozempic face?

No topical product, peptides included, has been tested in GLP-1 users. No registered trial is testing one either. Skincare can't replace lost fat.

General skincare still has a place: a basic routine with sunscreen, plus support for your skin barrier. Topical peptides such as copper peptides (GHK-Cu) have limited evidence for general skin quality, mostly from small or industry-linked studies. No one has shown that they affect GLP-1 facial changes or filler results. Treat them as optional everyday skincare, not as a fix.

What GLP-1 filler trials are underway?

Five registered trials are small (48 people or fewer), focused on injectables and mostly run by clinics. None has posted results.

We found no registered trial from Novo Nordisk or Eli Lilly with GLP-1 facial change as a primary endpoint.

What should you ask at a filler consultation for Ozempic face?

Since the evidence is limited, good questions matter more than brand names. Bring these:

1. Have you treated facial volume loss after GLP-1 weight loss? What happened when patients kept losing or regained weight?
2. Do you recommend waiting for stable weight or starting now, and why? (Either answer is expert opinion.)
3. Which product do you recommend, and what does its own labeling say about duration?
4. Can the product be reversed or dissolved if my face changes?
5. Will filler help my specific problem, or is it laxity that needs a different approach?
6. Do you have financial ties to the maker of the product you're recommending?
7. Can I have an itemized quote, including likely follow-up sessions?

Tell the injector which GLP-1 medication you take, including whether it's compounded, and about any existing filler.

Where the evidence stops

• No controlled trials. No randomized or placebo-controlled study has tested any filler or biostimulator in GLP-1 users.
• Industry funding dominates. The main study was funded, designed and analyzed by Galderma. The Radiesse series and the consensus paper have Merz and Allergan ties.
• Facial measurement is minimal. One retrospective imaging study of 20 people is the only objective GLP-1 face data. No prospective trial has photographed or scanned faces on semaglutide or tirzepatide.
• Timing is untested. Waiting vs starting early has never been compared head to head.
• Durability under changing weight is unknown.
• Safety signals are anecdotal. The nodule reports are case reports with a contested interpretation.
• Topicals are untested in this group.

FAQ

Are dermal fillers safe while still on Ozempic or another GLP-1 medication? No controlled safety data exist. The Galderma-funded study of 41 GLP-1 users reported no treatment-related adverse events (Lorenc et al., 2026). Separately, case reports describe nodules in existing filler after people started compounded tirzepatide, and a letter disputes the cause (Luke et al., 2026; letter). Tell both your prescriber and your injector.

Should I wait until my weight is stable before getting fillers? Experts disagree. Some advise waiting, while one review argues for starting biostimulation early (Frank et al., 2026), and a consensus paper says only that timing should be considered (Moradi et al., 2026). No trial compares the two. Never change your medication to time a treatment. Talk to your prescriber first.

How long do dermal fillers for Ozempic face last? No GLP-1-specific durability data exist. A Galderma-affiliated review says PLLA effects "persist for 2 years or longer" (Franco et al., 2026). For HA fillers, ask your injector what the specific product's labeling states.

Can fillers fix sagging skin or neck laxity after GLP-1 weight loss? Fillers add volume but don't tighten loose skin. Reviews list skin-tightening procedures and surgery as separate options for laxity (Humphrey et al., 2023). See Ozempic neck for more.

Will my face fill back in once my weight stabilizes? Many GLP-1 users report that cheek volume didn't return after months of stable weight. No study has tracked facial volume after GLP-1 weight stabilizes or after regain. See our Wegovy face before-and-after evidence review.

Can peptide creams replace fillers for Ozempic face? No. No topical product, peptides included, has been tested in GLP-1 users, and no topical can replace lost fat. Peptides are general skincare with limited evidence.

How much do fillers for Ozempic face cost? We don't publish price ranges because we found no sourced cost data specific to GLP-1 treatment. Costs depend on the product, the number of sessions and the provider, so ask for an itemized quote that includes follow-ups.

References

Bracketed text describes each paper. See the PubMed link for the full title and author list.

1. Sharma et al. [Midface volume change on CT/MRI after GLP-1 prescription]. Otolaryngol Head Neck Surg. 2025. Retrospective cohort, n=20, mean 321 days; funding not reported. https://pubmed.ncbi.nlm.nih.gov/40407186/
2. Daneshgaran G, et al. ["Ozempic face" in plastic surgery: systematic review with Google Trends]. Aesthet Surg J Open Forum. 2025. Systematic review, 23 articles; no funding or conflicts declared. https://pubmed.ncbi.nlm.nih.gov/40626110/
3. Mnajjed et al. [Google Trends analysis of "Ozempic face," filler and surgery searches, Jun 2022–Jun 2025]. Plast Reconstr Surg Glob Open. 2025. Search-trend analysis; no financial interest declared. https://pubmed.ncbi.nlm.nih.gov/41255744/
4. Couto et al. [Perceived age of facelift patients after massive weight loss]. Aesthetic Plast Surg. 2015. Retrospective, 7 patients vs 11 controls, 40 blinded raters. https://pubmed.ncbi.nlm.nih.gov/26311559/
5. Papoian et al. [Perceived age and attractiveness after bariatric weight loss]. Arch Plast Surg. 2015. Photo survey, 14 patients, ~100 raters; no conflicts declared. https://pubmed.ncbi.nlm.nih.gov/26430627/
6. Jafar et al. [Facial aging after surgical and medical weight loss]. Aesthet Surg J Open Forum. 2024. Systematic review, 13 studies + 1 abstract; funding not reported. https://pubmed.ncbi.nlm.nih.gov/39346804/
7. Orpheu et al. [Collagen and elastic fibers in skin after bariatric weight loss]. Obes Surg. 2010. Controlled histology, 40 vs 40 women, abdominal skin. https://pubmed.ncbi.nlm.nih.gov/19937152/
8. Lorenc et al. [PLLA-SCA plus HA filler for facial changes after GLP-1 weight loss]. Aesthet Surg J. 2026. Multicenter open-label, no control, n=41, 9-month follow-up; funded and designed by Galderma; NCT06351358. https://pubmed.ncbi.nlm.nih.gov/41243519/
9. Sarlos et al. [PLLA-SCA and HA after semaglutide weight loss]. Dermatol Surg. 2025. No abstract; funding not stated. https://pubmed.ncbi.nlm.nih.gov/40277199/
10. Durairaj et al. [Hyperdilute CaHA-CMC in the lower face during GLP-1 weight loss]. Aesthet Surg J Open Forum. 2025. Retrospective case series, n=4, 6 months; Merz product grant and Merz-employed co-author. https://pubmed.ncbi.nlm.nih.gov/41127050/
11. Moradi et al. [Expert consensus on aesthetic treatment of GLP-1-related facial changes]. Aesthet Surg J Open Forum. 2026. Expert consensus, 4 clinicians; Allergan-funded writing support. https://pubmed.ncbi.nlm.nih.gov/41768029/
12. Frank et al. [Facial changes with GLP-1 weight loss and treatment approach]. Dermatol Surg. 2026. Narrative review; funding not reported. https://pubmed.ncbi.nlm.nih.gov/42210888/
13. Franco et al. [Poly-L-lactic acid review]. Dermatol Surg. 2026. Narrative review; several Galderma-affiliated authors. https://pubmed.ncbi.nlm.nih.gov/42210881/
14. Humphrey et al. ["Ozempic face" and treatment options]. Facial Plast Surg. 2023. Narrative review; no conflicts declared. https://pubmed.ncbi.nlm.nih.gov/37541662/
15. Luke et al. [Facial nodules in prior filler after compounded tirzepatide]. JAAD Case Rep. 2026. Case report. https://pubmed.ncbi.nlm.nih.gov/42088720/
16. Moore et al. [Facial filler nodules after compounded tirzepatide]. JAAD Case Rep. 2026. Case report. https://pubmed.ncbi.nlm.nih.gov/42598502/
17. [Letter in response to filler-nodule case reports, arguing infection/biofilm not excluded]. JAAD Case Rep. 2026. Letter. https://pubmed.ncbi.nlm.nih.gov/42598504/
18. Wilding JPH, et al. [STEP 1: once-weekly semaglutide 2.4 mg in adults with overweight or obesity]. N Engl J Med. 2021. RCT, 68 weeks. https://pubmed.ncbi.nlm.nih.gov/33567185/
19. Wilding JPH, et al. [STEP 1 extension: weight regain after semaglutide withdrawal]. Diabetes Obes Metab. 2022. Off-treatment extension to week 120. https://pubmed.ncbi.nlm.nih.gov/35441470/
20. Wegovy (semaglutide) prescribing information. DailyMed SPL v19, PI revised 06/2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
21. openFDA drug adverse event (FAERS) API, queried Oct 10, 2026, 2:29 PM CT; generic names semaglutide and tirzepatide; MedDRA terms skin laxity, skin wrinkling, facial wasting, lipoatrophy. https://api.fda.gov/drug/event.json?search=patient.drug.openfda.generic_name:%22SEMAGLUTIDE%22+AND+patient.reaction.reactionmeddrapt.exact:%22Skin%20laxity%22&limit=1
22. ClinicalTrials.gov registry records: NCT06351358, NCT07478198, NCT07217743, NCT07221461, NCT07419854. https://clinicaltrials.gov/study/NCT07419854

Disclosure: This article is for general information and is not medical advice. Peptide Skincare Editorial Team members are not clinicians, and this article has not been medically reviewed. Decisions about injectables belong with a qualified, licensed provider, and decisions about GLP-1 medications belong with your prescriber. Never stop, skip or change a GLP-1 medication for skincare reasons. This article contains no affiliate links, and no company paid for or reviewed it.

For educational purposes only; not medical advice. See our disclaimer and research method.